The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician's Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum

Trial Profile

The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician's Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum

Discontinued
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Binimetinib (Primary) ; Doxorubicin liposomal; Paclitaxel; Topotecan
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms MILO
  • Sponsors Array BioPharma
  • Most Recent Events

    • 27 Jul 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2017.
    • 01 Apr 2016 Status changed from recruiting to discontinued, as per Array BioPharma media release.
    • 01 Apr 2016 According to Array BioPharma media release, status of this trial discontinued after a planned interim analysis showed that the Hazard Ratio for Progression Free Survival (PFS) crossed the predefined futility boundary.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top